GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Net Interest Income (for Banks)

Celyad Oncology (XBRU:CYAD) Net Interest Income (for Banks)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Celyad Oncology (XBRU:CYAD) Business Description

Industry
Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.